Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

Do America and Israel have the right to say to the Palestinians, “Get out of here and don’t come back?” Instead, don’t Israel ...